Gary A. Lyons
Independent Chairman of the BoardMr. Gary A. Lyons serves as Member of Senior Advisory Board at Healthcare Royalty Management, LLC. He serves as an Independent Chairman of the Board at Travere Therapeutics, Inc. since May 18, 2016. He had been an Independent Chairman of the Board at Rigel Pharmaceuticals, Inc. since November 2014 until March 2022. He had been Independent Director of Fresh Tracks Therapeutics, Inc. from August 2019 until October 02, 2023, and served as its Director since March 1997. Mr. Lyons served as the President and Chief Executive Officer of Neurocrine Biosciences, Inc. from February 1993 to January 2008. From 1983 to 1993, Mr. Lyons held various executive positions at Genentech Inc. including Vice President of Business Development, Vice President of Sales and Director of Sales & Marketing. He has management experience in the biotechnology and pharmaceutical industries. Mr. Lyons has served as the President and Chief Executive Officer of GL Advisors, a biotechnology advisory firm, since 2015. Mr. Lyons served as a Member of the Board of Directors of Vical Incorporated from March 1997 until the consummation of the merger with Private Brickell in August 2019. He served as a Director of Sales at American Critical Care from 1980 to 1983. From 1973 to 1983, he worked with American Critical Care. He served as an Executive Chairman of NeurogesX, Inc. since April 2011. Mr. Lyons had been an Independent Director at Cytori Therapeutics, Inc. from October 09, 2013, until January 30, 2019. He has been an Independent Director at Travere Therapeutics, Inc. since October 9, 2014. He served as an Independent Director of Rigel Pharmaceuticals, Inc. from October 05, 2005 to May 22, 2024, and served as its Lead Independent Director since February 4, 2014. He served as an Independent Director at Eledon Pharmaceuticals, Inc from May 2017 until June 21, 2023. Mr. Lyons has been an Independent Director of Neurocrine Biosciences, Inc. since joining in February 1993. He served as a Director of KaloBios Pharmaceuticals, Inc. from January 26, 2011, to November 19, 2015. He served as a Director of Poniard Pharmaceuticals, Inc from July 2009 to January 2, 2012. He served on the Board of Directors of Facet Biotech Corporation until 2010. He served as a Director of Desert Gateway Inc. until December 2012. He served as a Director of NeurogesX, Inc. since April 2011. He served as Director of PDL BioPharma, Inc. from July 16, 2008, to December 18, 2008. He served as the Director of AbbVie Biotherapeutics Inc. since November 2008. Mr. Lyons served as a Director of Intrabiotics Pharmaceuticals Inc. from December 1999 to June 2005. Mr. Lyons continues to be a valuable Member of the Board in part due to his extensive experience of negotiating and developing collaborative relationships, his sales expertise and his track record of assessing the market for pharmaceutical candidates, all of which are key to its success. Mr. Lyons was responsible for international licensing, acquisitions and partnering for Genentech's Corporate Venture Program and has operating responsibility for two subsidiaries, Genentech Canada, Inc. and Genentech Limited. He holds a B. S. in Marine Biology from the University of New Hampshire in 1973 and an MBA/M. M. Degree from the Northwestern University, JL Kellogg Graduate School of Management in 1983.
Positions
- Company NameTravere Therapeutics, Inc.Stock CodeTVTXPositionIndependent Chairman of the BoardColleagues
- EMEric M. DubePresident, CEO & Director
- CCChristopher ClineChief Financial Officer
- WEWilliam E. RoteChief Research Officer
- PHPeter HeermaChief Commercial Officer
- JIJula InrigExecutive VP, Head of Research & Development and Chief Medical Officer
- JAJeffrey A. MecklerIndependent Director
- TPTimothy P. CoughlinIndependent Director
- JAJohn A. OrwinIndependent Director
